Ownership and insider activity for PolyPid Ltd. (PYPD): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials.
Price
| Price | $5.21 |
| Market Cap | $99M |
| Exchange | NASDAQ |
| Country | IL |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-05-11 | Warshavsky Ori | A-Award | 46,000 | $205K |
| 2026-05-11 | Missulawin Jonathan | A-Award | 49,000 | $219K |
| 2026-05-11 | Hazan Dalit Fellous | A-Award | 75,000 | $334K |
| 2026-07-15 | Barenholz Yechezkel | A-Award | 9,132 | $41K |
| 2026-07-15 | Stein Robert Benjamin | A-Award | 9,132 | $41K |
| 2026-07-15 | Dror-Darwish Nir | A-Award | 9,132 | $41K |
| 2026-07-15 | BenAmram Joseph | A-Award | 9,132 | $41K |
| 2026-07-15 | Krinsky Itzhak | A-Award | 9,132 | $41K |
| 2026-07-15 | Story Brooke | A-Award | 9,132 | $41K |
| 2026-07-15 | Akselbrad Dikla Czaczkes | A-Award | 149,000 | $665K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.2M | $3.9M | $7.3M | $3.9M | $4.3M | $9.8M | $8.6M | $5.6M | $15.6M | $6.4M |
| Short-term Investments | $7.5M | $14.0M | 0 | $22.7M | $40.2M | $22.4M | $4.0M | 0 | 0 | $6.5M |
| Receivables | $28000 | $28000 | $24000 | $18000 | $139000 | $118000 | $298000 | 0 | 0 | 0 |
| Inventory | 0 | 0 | -$24000 | $351000 | 0 | 0 | 0 | 0 | 0 | $1.1M |
| Total Current Assets | $18.3M | $18.7M | $8.0M | $27.4M | $47.2M | $34.8M | $14.2M | $6.1M | $16.6M | $15.2M |
| Property, Plant & Equipment | $847000 | $2.9M | $6.2M | $6.1M | $5.9M | $8.8M | $11.7M | $9.2M | $8.4M | $6.8M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $19.2M | $23.0M | $14.5M | $33.8M | $75.8M | $44.2M | $26.0M | $15.4M | $25.2M | $22.3M |
| Accounts Payable | $778000 | $2.0M | $1.1M | $1.6M | $974000 | $4.1M | $1.1M | $772000 | $2.4M | $2.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $4.0M | $4.0M | $6.8M | $988000 |
| Total Current Liabilities | $1.7M | $3.4M | $3.7M | $2.6M | $2.9M | $8.1M | $8.6M | $7.3M | $12.7M | $7.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $7.6M | $6.4M | $634000 | 0 |
| Total Liabilities | $53.2M | $111.6M | $96.2M | $2.8M | $3.1M | $8.3M | $20.1M | $17.5M | $17.5M | $11.3M |
| Retained Earnings | -$36.6M | -$92.3M | -$86.4M | -$93.3M | -$132.3M | -$174.9M | -$214.4M | -$238.3M | -$267.3M | -$301.5M |
| Total Equity | -$34.0M | -$88.6M | -$81.7M | $30.9M | $72.8M | $36.0M | $5.8M | -$2.1M | $7.7M | $11.0M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | $13.7M | $11.8M | $9.6M | $2.8M |
| Net Debt | -$17.8M | -$17.9M | -$7.3M | -$26.6M | -$44.5M | -$32.2M | $1.1M | $6.2M | -$6.0M | -$10.1M |
| Working Capital | $16.6M | $15.4M | $4.3M | $24.8M | $44.3M | $26.7M | $5.6M | -$1.2M | $3.9M | $7.5M |
Financial Health
| Debt / Equity | 0.29 |
| Current Ratio | 1.35 |
Profitability
| Return on Equity | -311.07% |
| Return on Invested Capital | 11.71% |
| Return on Assets | -206.78% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANVS · ATNM · BCAB · BTAI · CELU · EVAX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of PYPD: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks